Detection of 1p19q deletion by real-time comparative quantitative PCR

Biomarker Insights

Volumn 7, Issue , 2012, Pages 9-17

  Chaturbedi, Abhishek ^a   Yu, Liping ^b   Linskey, Mark E ^a   Zhou, Yi Hong ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Ziren Research LLC   (United States)

Author keywords

1p19q deletion; Glioblastoma multiforme; Glioma; Oligodendroglial tumors; Real time comparative quantitative PCR

Indexed keywords

NOTCH2 RECEPTOR; TRANSCRIPTION FACTOR E2F2;

ARTICLE; ASTROCYTOMA; CANCER PROGNOSIS; CHROMOSOME 19Q; CHROMOSOME 1P; CHROMOSOME DELETION; COMPARATIVE QUANTITATIVE POLYMERASE CHAIN REACTION; COPY NUMBER VARIATION; E2F2 GENE; ERC2 GENE; FLUORESCENCE IN SITU HYBRIDIZATION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; MARKER GENE; NOTCH2 GENE; OLIGODENDROGLIOMA; PLAUR GENE; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SPAG16 GENE; SPOCK1 GENE;

EID: 84864808395     PISSN: None     EISSN: 11772719     Source Type: Journal    
DOI: None     Document Type: Article

References (33)

1. Ransom DT, Ritland SR, Kimmel DW, et al. Cytogenetic and loss of heterozygosity studies in ependymomas, pilocytic astrocytomas, and oligodendrogliomas. Genes Chromosomes Cancer. Nov 1992;5(4):348-56.
2. Bello MJ, Vaquero J, de Campos JM, et al. Molecular analysis of chromosome 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors. Int J Cancer. Apr 15, 1994;57(2):172-5.
3. Felsberg J, Erkwoh A, Sabel MC, et al. Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol. Apr 2004;14(2):121-30.
4. Okamoto Y, Di Patre PL, Burkhard C, et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol. Jul 2004;108(1):49-56.
5. Smith JS, Perry A, Borell TJ, et al. Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. J Clin Oncol. Feb 2000;18(3):636-45.
6. Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. Oct 15, 2006;66(20):9852-61.
7. Bauman GS, Ino Y, Ueki K, et al. Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas. Int J Radiat Oncol Biol Phys. Oct 1, 2000;48(3):825-30.
8. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst. Oct 7, 1998;90(19):1473-9.
9. Hoang-Xuan K, Capelle L, Kujas M, et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol. Aug 1, 2004;22(15):3133-8.
10. Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer. Apr 15, 2006;106(8):1759-65.
11. Cairncross G, Berkey B, Shaw E, et al. Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402. J Clin Oncol. Jun 20, 2006;24(18):2707-14.
12. Lassman AB, Iwamoto FM, Cloughesy TF, et al. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. Jun 2011;13(6):649-59.
13. Ino Y, Betensky RA, Zlatescu MC, et al. Molecular subtypes of anaplastic oligodendroglioma: implications for patient management at diagnosis. Clin Cancer Res. Apr 2001;7(4):839-45.
14. Reifenberger G, Louis DN. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J Neuropathol Exp Neurol. Feb 2003;62(2):111-26.
15. Smith JS, Alderete B, Minn Y, et al. Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype. Oncogene. Jul 15, 1999;18(28):4144-52.
16. Reddy KS. Assessment of 1p/19q deletions by fluorescence in situ hybridization in gliomas. Cancer Genet Cytogenet. Jul 15, 2008;184(2):77-86.
17. CBTRUS. Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2004-2006. Central Brain Tumor Registry of the United States. 2010.
18. katz MH. Multivariable Analysis. Cambridge: Cambridge University Press; 1999.
19. Zhou YH, Raj VR, Siegel E, Yu L. Standardization of gene expression quantification by absolute real-time qRT-PCR system using a single standard for marker and reference genes. Biomarker Insights. 2010;5:79-85.
20. Jeuken JW, von Deimling A, Wesseling P. Molecular pathogenesis of oligodendroglial tumors. J Neurooncol. Nov 2004;70(2):161-81.
21. Hartmann C, Mueller W, von Deimling A. Pathology and molecular genetics of oligodendroglial tumors. J Mol Med (Berl). Oct 2004;82(10):638-55.
22. van den Bent MJ, Carpentier AF, Brandes AA, et al. Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial. J Clin Oncol. Jun 20, 2006;24(18):2715-22.
23. Barbashina V, Salazar P, Holland EC, Rosenblum MK, Ladanyi M. Allelic losses at 1p36 and 19q13 in gliomas: correlation with histologic classification, definition of a 150-kb minimal deleted region on 1p36, and evaluation of CAMTA1 as a candidate tumor suppressor gene. Clin Cancer Res. Feb 1, 2005;11(3):1119-28.
24. Boulay JL, Miserez AR, Zweifel C, et al. Loss of NOTCH2 positively predicts survival in subgroups of human glial brain tumors. PLoS One. 2007;2(6):e576.
25. Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP. Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol. Nov 1994;145(5):1175-90.
26. Mohapatra G, Bollen AW, Kim DH, et al. Genetic analysis of glioblastoma multiforme provides evidence for subgroups within the grade. Genes Chromosomes Cancer. Mar 1998;21(3):195-206.
27. Ino Y, Silver JS, Blazejewski L, et al. Common regions of deletion on chromosome 22q12.3-q13.1 and 22q13.2 in human astrocytomas appear related to malignancy grade. J Neuropathol Exp Neurol. Aug 1999;58(8):881-5.
28. Jeuken JW, Sprenger SH, Wesseling P, et al. Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. J Neuropathol Exp Neurol. Jun 1999;58(6):606-12.
29. Jeuken JW, Sprenger SH, Boerman RH, et al. Subtyping of oligoastrocytic tumours by comparative genomic hybridization. J Pathol. May 2001;194(1):81-7.
30. Ginzinger DG, Godfrey TE, Nigro J, et al. Measurement of DNA copy number at microsatellite loci using quantitative PCR analysis. Cancer Res. Oct 1, 2000;60(19):5405-9.
31. Nigro JM, Takahashi MA, Ginzinger DG, et al. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. Am J Pathol. Apr 2001;158(4):1253-62.
32. Jeuken J, Cornelissen S, Boots-Sprenger S, Gijsen S, Wesseling P. Multiplex ligation-dependent probe amplification: a diagnostic tool for simultaneous identification of different genetic markers in glial tumors. J Mol Diagn. Sep 2006;8(4):433-43.
33. Zhou YH, Hess KR, Raj VR, et al. Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomarker Insights. 2010;5:153-168.